Eli Lilly's Foundayo (orforglipron) showed significant weight loss results in women across all menopause stages in the ATTAIN-1 and ATTAIN-2 trials, including those with type 2 diabetes. Women lost up to 30.4 lbs (14.4%) in perimenopause and up to 28.2 lbs (14.1%) post-menopause, with meaningful reductions in waist circumference, indicating reduced abdominal fat and cardiometabolic risk. These findings highlight Foundayo's potential as an effective obesity treatment during menopause, a period often linked with weight gain and increased health risks. The drug is FDA-approved for chronic weight management and continues to be studied for other conditions.
The Dow Jones Industrial Average reached a new record after a 2% gain, with the S&P 500 also rising 0.4%. Healthcare stocks led the market rally, driven by strong gains in insurers like Humana and Centene, and drugmakers such as UnitedHealth Group an...
PatentVest released a report analyzing 20 muscle-preservation programs aimed at improving long-term obesity treatment outcomes by preserving lean muscle during GLP-1 therapy. The report highlights growing industry interest, strategic acquisitions by ...
PatentVest released a report analyzing 20 muscle-preservation programs aimed at improving long-term obesity treatment outcomes by preserving lean muscle mass alongside GLP-1 therapies. This emerging category is gaining industry attention due to its p...
The 4-Factor Dividend Growth Strategy, inspired by the Schwab US Dividend Equity ETF (SCHD), targets high-quality dividend stocks using four specific metrics. Since its inception, it has delivered an average 12-month return of 16.94%, outperforming S...
Weight Watchers has partnered with Eli Lilly's digital platform LillyDirect to offer its Med+ program, combining GLP-1 medication access with clinical and behavioral support. This integration aims to provide patients nationwide with a comprehensive w...
